Document Detail

Cell cycle arrest by oxaliplatin on cancer cells.
MedLine Citation:
PMID:  17391289     Owner:  NLM     Status:  MEDLINE    
Oxaliplatin (L-OHP) is the only platinum compound to show activity in colorectal cancer. We evaluated the cytotoxicity of L-OHP on four human cancer cell lines and its influence on the cell cycle, when treated during long exposure (72 h) and different post-incubation times (24 or 72 h). We used a panel of cell lines: HT29 (colon cancer), MCF7 (breast cancer), Hela (uterine cervix) and A549 (lung adenocarcinoma). Inhibition concentration (IC)(50) was assessed by MTT assay. Cell cycle modifications were determined using dual parameter bromodeoxyuridine and propidium iodide. L-OHP yielded a superior cytotoxicity on HT29 and MCF7 relative to Hela and A549 after treatment, the post-incubations demonstrate that growth inhibition was irreversible for HT29 and Hela cell lines contrary to MCF7 and A549. The main effects of L-OHP are G2/M cell cycle arrest and transient S phase delay. Taken together, L-OHP treatment results on HT29, MCF7 and Hela, are in favor of lengthening the infusion duration to patients during further clinical trials.
Sara William-Faltaos; Dany Rouillard; Philippe Lechat; Gérard Bastian
Related Documents :
19481339 - Cyclosporine a inhibits colorectal cancer proliferation probably by regulating expressi...
20132219 - Girding for migratory cues: roles of the akt substrate girdin in cancer progression and...
19596269 - Hdac inhibitors, ms275 and sbha, enhances cytotoxicity induced by oxaliplatin in the co...
20392999 - Rapamycin-mediated foxo1 inactivation reduces the anticancer efficacy of rapamycin.
20485289 - Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells.
18607509 - Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in ...
17347989 - A new variant database for mismatch repair genes associated with lynch syndrome.
17094429 - Recent progress in target therapy in colorectal cancer.
17267619 - Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal ca...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  21     ISSN:  0767-3981     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-29     Completed Date:  2007-06-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  165-72     Citation Subset:  IM    
Pharmacology Department, Faculty of Medicine, Pitie-Salpetriere Hospital, 91 Boulevard de l'Hôpital, Door: 417-418, 75634 Paris Cedex 13, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  pharmacology*
Cell Cycle / drug effects*
Cell Line, Tumor
Cell Survival / drug effects*
Flow Cytometry
Infusions, Intravenous
Organoplatinum Compounds / administration & dosage,  pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 36015-30-2/Propidium; 59-14-3/Bromodeoxyuridine; 63121-00-6/oxaliplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant s...
Next Document:  A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after car...